ArticleiScience2024
Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation.
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of IL-4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials.The Australasian journal of dermatology · 2026Pooled it
- Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic Dermatitis.International journal of dermatology · 2026Trial
- Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 Trial.Advances in therapy · 2025Trial
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trial.Nature medicine · 2025Trial
- Stapokibart, a novel monoclonal antibody targeting the interleukin 4 receptor α subunit: Promising results in a retrospective cohort of patients with bullous pemphigoid.JAAD case reports · 2026Article
- Atopic Dermatitis: New Targets and Emerging Systemic Therapies.American journal of clinical dermatology · 2026Review
- A short-course and season-oriented Stapokibart strategy for moderate-to-severe seasonal allergic rhinitis: Real-world evidence from Northern China.The World Allergy Organization journal · 2026Article
- Baseline Inflammatory Biomarkers and Disease Burden for Predicting Response to Stapokibart in CRSwNP.Diagnostics (Basel, Switzerland) · 2026Article
- From Tregs to tissue remodelling: FOXP3 and IL-35 in the inflammatory landscape of nasal polyps.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets.Aging cell · 2026Review
- UC-MSCs-derived exosomal circFOXP1 alleviates allergic rhinitis through EZH2/EGR1/Blimp-1 axis.Respiratory research · 2026Article
- Current Insights Into Individualized Diagnosis and Treatment of Allergic Rhinitis Based on Phenotype and Endotype.World journal of otorhinolaryngology - head and neck surgery · 2026Review
- Successful Treatment of Refractory Chronic Spontaneous Urticaria with Stapokibart After Omalizumab Failure: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden.Frontiers in immunology · 2026Article
- Case Report: Olfactory loss as the sentinel manifestation of type 2 chronic rhinosinusitis without polyps: response to IL-4Rα inhibition with stapokibart - a case series.Frontiers in immunology · 2026Article
- IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies.Frontiers in immunology · 2026Review
- Rapid Improvement of Acute Eczematous Facial Dermatitis During Pregnancy Following Stapokibart Therapy: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- The Therapeutic Role of Biologics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): A Review of the Current Evidence.Therapeutics and clinical risk management · 2026Review
- Successful management of DPP-4 inhibitor-induced bullous pemphigoid with Stapokibart injection in an elderly diabetic patient: a case report.Frontiers in medicine · 2026Article
- Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stapokibart (CM310) is a humanized IL-4Rα monoclonal antibody currently undergoing phase 3 trials for type 2 inflammatory diseases. In contrast to dupilumab, which bound exclusively to human IL-4Rα, stapokibart demonstrated cross-species reactivity to IL-4Rα from human, cynomolgus monkey, and rat. Stapokibart exhibited comparable blocking activity to dupilumab. Epitope mapping revealed that stapokibart bound to distinct sites on IL-4Rα compared to dupilumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.